Progenics Pharmaceuticals, Inc. (PGNX) Posts Q1 EPS Loss of $0.69, Misses Consensus by 18c
Tweet Send to a Friend
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
